A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Daily for 28 Days to Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
At a glance
- Drugs TP 0184 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Tolero Pharmaceuticals
- 25 Jul 2018 According to a Tolero Pharmaceuticals media release, first patients has been dosed in this study.
- 25 Jul 2018 Status changed from not yet recruiting to recruiting, according to a Tolero Pharmaceuticals media release.
- 14 Feb 2018 New trial record